| Document |
Document Title |
|
WO/2007/098169A1 |
The present invention is directed tojcjnnoline compounds of formula (I) that are PDE 1 inhibitors, pharmaceutical compositions containing such compounds and process for preparing such compounds. This invention is also directed to methods...
|
|
WO/2007/075783A2 |
This invention provides compounds of Formula (I), having the structure where G1, G2, G3, G4, A1, A2, Y1, Y2, L1, Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing ca...
|
|
WO2007058392A9 |
It is intended to provide a novel heterocyclic compound having an HCV entry inhibition activity and a medicinal application thereof. The invention relates to the use of the heterocyclic compound represented by the general formula [1]: [w...
|
|
WO/2007/073283A1 |
This invention relates to novel Cinnoline -based compounds and their pharmaceutically acceptable salts, tautomers or in vivo- hydrolysable precursors, compositions and methods of use thereof . These novel compounds provide a treatment or...
|
|
WO/2007/071358A1 |
The present invention relates to novel nicotinic acid derivatives, of formula (I), wherein the substituents are defined in the specification, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
|
|
WO/2007/071311A1 |
2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R, R0 R1, R2, R3, and R4 have the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions co...
|
|
WO/2007/065518A1 |
Compounds of the formula (I) in which R1, R2 and R3 are as defined in claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be used in applications including the treatment of tumours.
|
|
WO/2007/066615A1 |
Disclosed is a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt, which can be used as a pregnane receptor activator. (I) wherein R1 represents a cycloh...
|
|
WO/2007/063934A1 |
Disclosed is a compound represented by the formula below or a pharmaceutically acceptable salt thereof: (1) wherein the ring A represents a heterocyclic ring; the ring B represents a carbocyclic ring or a heterocyclic ring; P1 and P2 ind...
|
|
WO/2007/048802A1 |
The present invention relates to (hetero)aryl compounds of general formula (I) wherein the groups and radicals A, B, Q, W, X, Y, Z, R1, R2, R4a, R4b, R5a, R5b, have the meanings given in claim 1. Moreover the invention relates to pharmac...
|
|
WO/2007/048065A2 |
A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1 and R2 are defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.
|
|
WO/2007/045861A1 |
There are provided according to the invention novel compounds of formula (I).
|
|
WO/2007/044085A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where J, K, L, M, W, V, R2 and R3 ...
|
|
WO/2007/039463A1 |
The present invention provides compounds of formula (I) where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further prov...
|
|
WO/2007/031791A1 |
A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1′, -L1-A1-A1′, -A1-L1-A1′, -A1-Y1-A1′, -A1-Het1-A1′, -L1-...
|
|
WO/2007/030567A2 |
Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.
|
|
WO/2007/026623A1 |
A process for producing 3-amino-6-chloropyridazine, characterized in that 3,6-dichloropyridazine is reacted with ammonia in the presence of a water-soluble C5-C1000 polyether.
|
|
WO/2007/026624A1 |
Disclosed is a method for producing a 2,3-dihydropyridazine compound represented by the formula (2) below wherein a salt made from a bromoacetic acid and an amine compound is reacted with a pyridazine compound represented by the formula ...
|
|
WO/2007/027733A2 |
A terminal communicates with a serving base station and at least one soft handoff (SHO) base station for soft handoff on the reverse link in a wireless communication system. In one design, the serving base station schedules the terminal ...
|
|
WO/2007/026771A1 |
A high-content injection for intravenous drip which is prepared by adding an acidic pH regulator to an aqueous suspension containing 4-(N-(4-morpholin-4-yl)butyl)carbamoylmethyl)-5,6,7,8-tetrah
ydrophthalazin-1(2H)-one (Compound A) and d...
|
|
WO/2007/027599A1 |
This invention provides compounds of Formula (I) having the structure where R1, R2, R3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (I...
|
|
WO/2007/022845A1 |
The invention relates to compounds of formula (1) and to the use thereof in organic electroluminescent devices. The compounds of formula (1) are used as host material or as a dopant in the emitting layer and/or as hole transport material...
|
|
WO/2007/022380A2 |
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula...
|
|
WO/2007/021858A2 |
The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. T...
|
|
WO/2007/014607A1 |
The invention relates to compounds of formula (I), wherein R, X, R 1, R2,R3, R4 and R5 have the significances specified in claim 1, wherein said compounds are embodied in the form of CHK1- CHK2- and SGK kinase inhibitors and can be used,...
|
|
WO/2007/014226A2 |
Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are rel...
|
|
WO/2007/009913A1 |
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2007/003521A2 |
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions, as 11 beta-hydroxysteroid dehydroge...
|
|
WO/2007/003077A1 |
A substituted pyridazinyl amine derivatives of fomula I, and pharmceutical acceptalbe salts or hydrates thereof, preparation method, pharmaceutical compositions containing said compounds, and their use as picorna virus inhibitors in the ...
|
|
WO/2007/002313A2 |
The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11...
|
|
WO/2006/136304A1 |
The invention relates to compounds of the formula (I), in which R1 , R2, R3, R4, R5, R6 and X have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the tre...
|
|
WO/2006/132442A1 |
Disclosed are a compound represented by the general formula (I): (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the like; and others. The compound or pharmaceutically acceptable...
|
|
WO/2006/132811A2 |
The present invention relates to AMPA receptor potentiators of Formula (I), formulations comprising them, methods for their use, and intermediates useful for their preparation.
|
|
WO/2006/127379A2 |
The present invention relates to compounds, and uses thereof, having the chemical formula: or a pharmaceutically acceptable salt or prodrug thereof, wherein the compound modulates the activity of PAR2 or a PAR2 subtype and thereby may be...
|
|
WO/2006/124996A2 |
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: (I) including steroisomers, prodrug...
|
|
WO/2006/115221A1 |
It is intended to provide a novel compound having an excellent PDE4 inhibitory activity and TNF-&agr production-suppressing activity. It is also intended to provide a preventive and therapeutic agent for atopic dermatitis or the like. Th...
|
|
WO/2006/113650A1 |
A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell ...
|
|
WO/2006/108714A2 |
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (I) and to a method for the production and the use thereof in the form of antiphlogistics.
|
|
WO/2006/108591A1 |
The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schiz...
|
|
WO/2006/109817A1 |
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1 represents a branched alkyl group having 3 to 9 carbon atoms or the like; R2 represents a 6-membered heteroaryl group having 1 or 2 n...
|
|
WO/2006/108107A1 |
Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, an...
|
|
WO/2006/104172A1 |
A preventive and/or therapeutic agent for rheumatoid arthritis. There is provided a preventive and/or therapeutic agent for rheumatoid arthritis, comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyri
dazin-3-one and a C...
|
|
WO/2006/101521A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferebly a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, ...
|
|
WO/2006/101058A1 |
Disclosed is a method for producing 3,6-dichloropyridazine-1-oxide which is characterized by reacting 3,6-dichloropyridazine with an acid anhydride and a hydrogen peroxide having a concentration of not more than 60% or a urea hydrogen pe...
|
|
WO/2006/100100A1 |
The invention relates to tetrahydronaphthalene derivatives of general formula (I), to a method for their production and to their use as anti-inflammatory agents.
|
|
WO/2006/097176A1 |
The invention relates to compounds of formula I, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meaning cited in claim 1, and which can be used for treating tumours.
|
|
WO/2006/094187A2 |
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula (I), wherein A1, A...
|
|
WO/2006/094034A1 |
This invention relates to cinnoline-based modulators of Liver X receptors (LXRs) of formula (I) wherein R2 is a ring containing residue, particularly a phenyl residue. These compounds are useful in the treatment of cardiovascular diseases.
|
|
WO/2006/091592A1 |
The present invention relates to naphthalene derivatives of formula (I) that are modulators of the glucocorticoid receptor, and to processes for the preparation and use of the same.
|
|
WO/2006/090235A1 |
The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, arylox...
|
